Ontology highlight
ABSTRACT: Background
Stathmin1 (STMN1) is a cytosolic phosphoprotein that regulates cellular microtubule dynamics and is known to have oncogenic activity. Despite several reports, its roles in gastric cancer (GC) remain unclear owing to a lack of analyses of highly metastatic cases. This study aimed to investigate STMN1 as a prognostic and predictive indicator of response to paclitaxel therapy in patients with GC, including inoperable cases.Methods
Immunohistochemical analysis of STMN1 was performed on both operable (n=95) and inoperable GC (n=61) samples. The roles of STMN1 in cancer cell proliferation and sensitivity to a microtubule-targeting drug, paclitaxel, were confirmed by knockdown experiments using GC cell lines.Results
Multivariate and Kaplan-Meier analyses demonstrated that high STMN1 was predictive of poor prognosis in both the groups. In the operable cohort, STMN1 expression correlated with cancer curability, recurrence, and resistance to adjuvant therapy. A correlation with paclitaxel resistance was observed in inoperable cases. Knockdown of STMN1 in GC cell lines inhibited proliferation and sensitised the cells to paclitaxel by enhancing apoptosis.Conclusions
STMN1 is a possible biomarker for paclitaxel sensitivity and poor prognosis in GC and could be a novel therapeutic target in metastatic GC.
SUBMITTER: Bai T
PROVIDER: S-EPMC5418450 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature
Bai Tuya T Yokobori Takehiko T Altan Bolag B Ide Munenori M Mochiki Erito E Yanai Mitsuhiro M Kimura Akiharu A Kogure Norimichi N Yanoma Toru T Suzuki Masaki M Bao Pinjie P Kaira Kyoichi K Asao Takayuki T Katayama Ayaka A Handa Tadashi T Gombodorj Navchaa N Nishiyama Masahiko M Oyama Tetsunari T Ogata Kyoichi K Kuwano Hiroyuki H
British journal of cancer 20170323 9
<h4>Background</h4>Stathmin1 (STMN1) is a cytosolic phosphoprotein that regulates cellular microtubule dynamics and is known to have oncogenic activity. Despite several reports, its roles in gastric cancer (GC) remain unclear owing to a lack of analyses of highly metastatic cases. This study aimed to investigate STMN1 as a prognostic and predictive indicator of response to paclitaxel therapy in patients with GC, including inoperable cases.<h4>Methods</h4>Immunohistochemical analysis of STMN1 was ...[more]